Evidence map›Paper›PMID 36267162›Full record

ArticleDermatology reports2022

Attitudes among dermatologists regarding actinic keratosis treatment options.

Gaia Moretta, Tonia Samela, Francesca Sampogna, Francesco Ricci, Fabio Carlesimo, Annarita Panebianco, Angelo Massimiliano D'Erme, Giovanni Di Lella, Sabatino Pallotta, Elena Dellambra and 2 more

Open access · goldAbstract read
In one paragraph

Article in Dermatology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Gaia MorettaIDI-IRCCS, Dermatological Research Hospital, Rome.
Tonia SamelaIDI-IRCCS, Dermatological Research Hospital, Rome.
Francesca SampognaIDI-IRCCS, Dermatological Research Hospital, Rome.
Francesco RicciIDI-IRCCS, Dermatological Research Hospital, Rome.
Fabio CarlesimoIDI-IRCCS, Dermatological Research Hospital, Rome.
Annarita PanebiancoIDI-IRCCS, Dermatological Research Hospital, Rome.
Angelo Massimiliano D'ErmeUnit of Dermatology, Livorno Hospital, Livorno, Italy.
Giovanni Di LellaIDI-IRCCS, Dermatological Research Hospital, Rome.
Sabatino PallottaIDI-IRCCS, Dermatological Research Hospital, Rome.
Elena DellambraIDI-IRCCS, Dermatological Research Hospital, Rome.
Damiano AbeniIDI-IRCCS, Dermatological Research Hospital, Rome.
Luca FaniaIDI-IRCCS, Dermatological Research Hospital, Rome.
Istituti di Ricovero e Cura a Carattere Scientifico · ITOspedale di Livorno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Actinic keratosis (AK) is considered a precancerous lesion that can develop into invasive squamous cell carcinoma. Its prevalence is increasing, and it is estimated that it affects between 1% and 44% of the adult population worldwide. Advanced age, fair skin phototypes, and cumulative sun exposure are the main risk factors for AK. Therapies for AK consists of lesion-directed treatment (

Indexed as

actinic keratosisdermatologynon-melanomaskin tumortherapy

Identifiers

PMID36267162
PMCPMC9577376
OpenAlexW4226087471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.